Mr. Bogatyrenko is a proven pharmaceutical executive, having served in multiple operational and consulting roles in the life sciences industry. Most recently he was a SVP, Business Development at Paratek Pharmaceuticals in Boston where he developed global and regional partnerships for its anti-infective products and led its U.S. alliance with Allergan. He is a Venture Partner at ATEM Capital in New York, where he developed commercial strategies for clients across a variety of therapeutic areas. Prior to ATEM, he held the position of Vice President and General Manager at Teva Specialty Pharmaceuticals. In this role, he directed biopharma and over-the-counter (OTC) women’s health business across emerging markets, and was responsible for business development of Teva’s women’s health portfolio, including biologics, small molecules, and OTC products. Yulii holds an MBA in Finance from L. Stern School of Business, NYU.
Yulii Bogatyrenko, a seasoned pharmaceutical executive, joins Nobilis Therapeutics as its Chief Operating Officer
by nobilistx | Oct 26, 2017 | Uncategorized |